File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Detection of hypermethylated genes in tumor and plasma of cervical cancer patients

TitleDetection of hypermethylated genes in tumor and plasma of cervical cancer patients
Authors
KeywordsCervical cancer
DAPK
MGMT
p16
Promoter CpG island hypermethylation
Issue Date2004
PublisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/ygyno
Citation
Gynecologic Oncology, 2004, v. 93 n. 2, p. 435-440 How to Cite?
AbstractObjective. The aim of this study is to investigate the prevalence of promotor CpG island methylation of the death-associated protein kinase (DAPK), p16, and O 6-methylguanine-DNA methyltransferase (MGMT) genes in both tumor and plasma samples of cervical cancers. Methods. Methylation-specific PCR (MSP) was employed to detect promotor CpG island methylation of the DAPK, p16, and MGMT genes in 85 surgical tumor tissue samples and 40 pretreatment plasma samples from cervical cancers. Results. Promotor CpG island methylation of DAPK, p16, and MGMT was detectable, respectively, in 60%, 28.2%, and 18.8% of cases of cervical tumor DNA; and in 40%, 10%, and 7.5% of cases of patients' plasma DNA. Moreover, at least one of the three methylated genes was detected in 75.3% (64/85) of cases of tumor and in 55% (22/40) of cases of plasma. Higher prevalence of methylation of DAPK was found in squamous cell carcinoma than in adenocarcinoma in both univariate and multivariate analysis. Methylation of p16 was significantly associated with that of MGMT in both univariate and multivariate analysis. The methylation pattern in primary tumor and plasma was found to be concordant in 23 patients with matched tissue and plasma samples. In cases positive for DAPK and p16 methylation in tumor, detection in the paired plasma sample was 64.3% (9/14) and 33.3% (3/9), respectively. Conclusions. Promotor CpG island methylation is a frequent event in cervical carcinogenesis. Detection of the methylated sequences in the circulation suggests that plasma DNA methylation warrants further study to determine its potential role in cancer management. © 2004 Elsevier Inc. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/87276
ISSN
2015 Impact Factor: 4.198
2015 SCImago Journal Rankings: 2.284
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYang, HJen_HK
dc.contributor.authorLiu, VWSen_HK
dc.contributor.authorWang, Yen_HK
dc.contributor.authorChan, KYKen_HK
dc.contributor.authorTsang, PCKen_HK
dc.contributor.authorKhoo, USen_HK
dc.contributor.authorCheung, ANYen_HK
dc.contributor.authorNgan, HYSen_HK
dc.date.accessioned2010-09-06T09:27:36Z-
dc.date.available2010-09-06T09:27:36Z-
dc.date.issued2004en_HK
dc.identifier.citationGynecologic Oncology, 2004, v. 93 n. 2, p. 435-440en_HK
dc.identifier.issn0090-8258en_HK
dc.identifier.urihttp://hdl.handle.net/10722/87276-
dc.description.abstractObjective. The aim of this study is to investigate the prevalence of promotor CpG island methylation of the death-associated protein kinase (DAPK), p16, and O 6-methylguanine-DNA methyltransferase (MGMT) genes in both tumor and plasma samples of cervical cancers. Methods. Methylation-specific PCR (MSP) was employed to detect promotor CpG island methylation of the DAPK, p16, and MGMT genes in 85 surgical tumor tissue samples and 40 pretreatment plasma samples from cervical cancers. Results. Promotor CpG island methylation of DAPK, p16, and MGMT was detectable, respectively, in 60%, 28.2%, and 18.8% of cases of cervical tumor DNA; and in 40%, 10%, and 7.5% of cases of patients' plasma DNA. Moreover, at least one of the three methylated genes was detected in 75.3% (64/85) of cases of tumor and in 55% (22/40) of cases of plasma. Higher prevalence of methylation of DAPK was found in squamous cell carcinoma than in adenocarcinoma in both univariate and multivariate analysis. Methylation of p16 was significantly associated with that of MGMT in both univariate and multivariate analysis. The methylation pattern in primary tumor and plasma was found to be concordant in 23 patients with matched tissue and plasma samples. In cases positive for DAPK and p16 methylation in tumor, detection in the paired plasma sample was 64.3% (9/14) and 33.3% (3/9), respectively. Conclusions. Promotor CpG island methylation is a frequent event in cervical carcinogenesis. Detection of the methylated sequences in the circulation suggests that plasma DNA methylation warrants further study to determine its potential role in cancer management. © 2004 Elsevier Inc. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/ygynoen_HK
dc.relation.ispartofGynecologic Oncologyen_HK
dc.subjectCervical canceren_HK
dc.subjectDAPKen_HK
dc.subjectMGMTen_HK
dc.subjectp16en_HK
dc.subjectPromoter CpG island hypermethylationen_HK
dc.subject.meshAdulten_HK
dc.subject.meshApoptosis Regulatory Proteinsen_HK
dc.subject.meshCalcium-Calmodulin-Dependent Protein Kinases - geneticsen_HK
dc.subject.meshCpG Islandsen_HK
dc.subject.meshDNA Methylationen_HK
dc.subject.meshDNA, Neoplasm - blooden_HK
dc.subject.meshFemaleen_HK
dc.subject.meshGenes, p16en_HK
dc.subject.meshHumansen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshO(6)-Methylguanine-DNA Methyltransferase - geneticsen_HK
dc.subject.meshPromoter Regions, Geneticen_HK
dc.subject.meshUterine Cervical Neoplasms - blood - enzymology - geneticsen_HK
dc.titleDetection of hypermethylated genes in tumor and plasma of cervical cancer patientsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0090-8258&volume=93&issue=2&spage=435&epage=440&date=2004&atitle=Detection+of+hypermethylated+genes+in+tumor+and+plasma+of+cervical+cancer+patientsen_HK
dc.identifier.emailLiu, VWS: vwsliu@hkusua.hku.hken_HK
dc.identifier.emailChan, KYK: kelvinc@pathology.hku.hken_HK
dc.identifier.emailKhoo, US: uskhoo@hku.hken_HK
dc.identifier.emailCheung, ANY: anycheun@hkucc.hku.hken_HK
dc.identifier.emailNgan, HYS: hysngan@hkucc.hku.hken_HK
dc.identifier.authorityLiu, VWS=rp00341en_HK
dc.identifier.authorityChan, KYK=rp00453en_HK
dc.identifier.authorityKhoo, US=rp00362en_HK
dc.identifier.authorityCheung, ANY=rp00542en_HK
dc.identifier.authorityNgan, HYS=rp00346en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.ygyno.2004.01.039en_HK
dc.identifier.pmid15099958-
dc.identifier.scopuseid_2-s2.0-1942508904en_HK
dc.identifier.hkuros86846en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-1942508904&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume93en_HK
dc.identifier.issue2en_HK
dc.identifier.spage435en_HK
dc.identifier.epage440en_HK
dc.identifier.isiWOS:000221120500026-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridYang, HJ=7408624370en_HK
dc.identifier.scopusauthoridLiu, VWS=7006405113en_HK
dc.identifier.scopusauthoridWang, Y=8637619000en_HK
dc.identifier.scopusauthoridChan, KYK=7406034195en_HK
dc.identifier.scopusauthoridTsang, PCK=7102404070en_HK
dc.identifier.scopusauthoridKhoo, US=7004195799en_HK
dc.identifier.scopusauthoridCheung, ANY=54927484100en_HK
dc.identifier.scopusauthoridNgan, HYS=34571944100en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats